TrialCancer science2011

Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.

Yoshinori Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.